Nomura: JD Health Exceeds Last Quarter Expectations; FY26 Profit Margin Forecast Appears Cautious
JD HEALTH Revenue Growth: JD HEALTH reported a 28% year-over-year increase in revenue for 2H25, exceeding market and broker forecasts, with a non-IFRS operating profit margin rising to 5%.
4Q25 Performance: The company's revenue for 4Q25 also saw a 27% YoY increase, surpassing broker expectations, while management guidance for FY26 suggests a high double-digit to 20% growth in revenue.
Cautious Management Outlook: JD HEALTH's management has adopted a cautious approach, leading to guidance that falls below market expectations for continuous profit margin expansion in FY26.
Nomura's Rating and Target Price: Nomura maintains a Buy rating for JD HEALTH with a target price of HKD80, reflecting confidence despite the cautious outlook from the company's management.
Trade with 70% Backtested Accuracy
Analyst Views on 06618
About the author
BofAS Maintains JD HEALTH's Target Price at HKD75 and Reiterates Buy Rating, Increases Revenue Growth Projection
Financial Performance: JD HEALTH reported a 26% year-on-year revenue growth to RMB73.4 billion, surpassing market expectations, with an adjusted net profit of RMB6.5 billion, a 36% increase from the previous year.
Future Projections: BofA Securities has raised its 2026 revenue growth forecast for JD HEALTH from 16% to 18%, while maintaining the adjusted net profit forecast at RMB6.6 billion, citing stable operating profit margins and investments in retail and AI.
Market Rating: BofA Securities reiterated a "Buy" rating for JD HEALTH and set a target price of HKD75, reflecting confidence in the company's continued performance.
Short Selling Activity: JD HEALTH experienced significant short selling activity, with a total of $315.63 million and a short selling ratio of 39.71%.
M Stanley Reduces JD HEALTH's Target Price to HKD66 and Adjusts EPS Projections Downward
Morgan Stanley's Revenue Forecasts: Morgan Stanley has increased its revenue forecasts for JD HEALTH (06618.HK) for 2026-28 by 5% to 7%, anticipating continued growth in online pharmaceutical sales, with a projected 18% revenue growth in 2026.
Earnings Predictions: Despite the revenue growth, Morgan Stanley expects JD HEALTH's adjusted operating profit for 2026 to remain flat and has reduced its adjusted EPS forecasts for 2026-28 by 4% to 6%.
Target Price Adjustment: The target price for JD HEALTH has been lowered from HKD70 to HKD66, reflecting the updated earnings outlook.
Short Selling Data: JD HEALTH is experiencing significant short selling, with a total of $315.63 million and a short selling ratio of 39.710%.
Nomura: Positive Revenue Forecast for JD HEALTH (06618.HK); Maintains Buy Rating with Target Price of HKD80
Revenue Growth: JD Health reported a 28% year-on-year revenue growth in 2H25, exceeding market and Nomura's expectations, with an estimated 27% growth in 4Q25.
Operating Profit Increase: The company's non-IFRS operating profit surged by 88% year-on-year to RMB1.9 billion, with an operating profit margin of 5%, surpassing Nomura's forecast.
Future Projections: For 2026, JD Health anticipates steady revenue growth, although the rate is expected to decline to a high single-digit to 20% due to a high base effect.
Stock Rating: Nomura maintained a Buy rating for JD Health with a target price set at HKD80.
BofAS: JD HEALTH (06618.HK) Surpasses Quarterly Expectations; Target Price Set at $75 and Buy Rating Maintained
Company Performance: JD Health reported results that exceeded expectations for Q1-Q4 2025, prompting BofA Securities to host an investor meeting with management, who expressed confidence in capturing a larger share of the pharmacy market.
Strategic Focus: The company's strategy includes enhancing cooperation with pharmaceutical firms for new drug launches, developing high-potential health supplements, and advancing a comprehensive model for medical devices that integrates hardware, software, services, and ecosystem.
Growth Forecast: BofA Securities raised its revenue growth forecast for JD Health to 18% year-over-year for 2026, primarily driven by accelerated growth in the pharmaceutical sector, while maintaining the adjusted net profit forecast at RMB6.6 billion.
Market Rating: The broker maintained a "Buy" rating for JD Health, setting a target price of $75, despite expectations of flat net profit growth for the year.
HSI Rises 435 Points as JD-SW Jumps 10% and JD LOGISTICS Soars 23%
Hong Kong Stock Market Performance: Hong Kong stocks saw significant gains, with the HSI rising 1.7% to 25,757, the HSCEI up 2.1% to 8,628, and the HSTECH increasing 3.2% to 4,947, alongside a total market turnover of $292.766 billion.
JD Series Surge: JD-SW shares surged nearly 10% to $106.6 following positive results, while JD LOGISTICS experienced a remarkable 23% increase, making it the largest gainer among blue chips.
Tech Stocks Rally: Major tech companies like TENCENT, BABA-W, and MEITUAN-W saw their stock prices rise between 3.1% and 5.2%, reflecting a broader positive trend in the tech sector.
BILIBILI-W Decline: Despite reporting a 94% increase in adjusted net profit, BILIBILI-W's stock price fell by 4.5%, contrasting with other companies that experienced gains.
HSBC Research Anticipates Continued Strong Revenue Growth for JD HEALTH (06618.HK) This Year, Raises Target Price to $80
Annual Results Announcement: JD HEALTH reported strong quarterly results, highlighting the effectiveness of its strategy focused on enhancing supply chain capabilities and user engagement, as noted by HSBC Global Research.
Competitive Advantage: The company's solid competitive position has improved user perception and strengthened partnerships with pharmaceutical firms, creating a beneficial cycle for growth.
Revenue Growth Forecast: HSBC Global Research expressed confidence in JD HEALTH's sustained revenue growth, particularly in prescription drugs, and raised its revenue forecasts for 2026 and 2027 by 1%.
Target Price Adjustment: Following a valuation update, HSBC increased JD HEALTH's target price from $77.5 to $80 while maintaining a "Buy" rating.
BofAS Maintains JD HEALTH's Target Price at HKD75 and Reiterates Buy Rating, Increases Revenue Growth Projection
Financial Performance: JD HEALTH reported a 26% year-on-year revenue growth to RMB73.4 billion, surpassing market expectations, with an adjusted net profit of RMB6.5 billion, a 36% increase from the previous year.
Future Projections: BofA Securities has raised its 2026 revenue growth forecast for JD HEALTH from 16% to 18%, while maintaining the adjusted net profit forecast at RMB6.6 billion, citing stable operating profit margins and investments in retail and AI.
Market Rating: BofA Securities reiterated a "Buy" rating for JD HEALTH and set a target price of HKD75, reflecting confidence in the company's continued performance.
Short Selling Activity: JD HEALTH experienced significant short selling activity, with a total of $315.63 million and a short selling ratio of 39.71%.
M Stanley Reduces JD HEALTH's Target Price to HKD66 and Adjusts EPS Projections Downward
Morgan Stanley's Revenue Forecasts: Morgan Stanley has increased its revenue forecasts for JD HEALTH (06618.HK) for 2026-28 by 5% to 7%, anticipating continued growth in online pharmaceutical sales, with a projected 18% revenue growth in 2026.
Earnings Predictions: Despite the revenue growth, Morgan Stanley expects JD HEALTH's adjusted operating profit for 2026 to remain flat and has reduced its adjusted EPS forecasts for 2026-28 by 4% to 6%.
Target Price Adjustment: The target price for JD HEALTH has been lowered from HKD70 to HKD66, reflecting the updated earnings outlook.
Short Selling Data: JD HEALTH is experiencing significant short selling, with a total of $315.63 million and a short selling ratio of 39.710%.
Nomura: Positive Revenue Forecast for JD HEALTH (06618.HK); Maintains Buy Rating with Target Price of HKD80
Revenue Growth: JD Health reported a 28% year-on-year revenue growth in 2H25, exceeding market and Nomura's expectations, with an estimated 27% growth in 4Q25.
Operating Profit Increase: The company's non-IFRS operating profit surged by 88% year-on-year to RMB1.9 billion, with an operating profit margin of 5%, surpassing Nomura's forecast.
Future Projections: For 2026, JD Health anticipates steady revenue growth, although the rate is expected to decline to a high single-digit to 20% due to a high base effect.
Stock Rating: Nomura maintained a Buy rating for JD Health with a target price set at HKD80.
BofAS: JD HEALTH (06618.HK) Surpasses Quarterly Expectations; Target Price Set at $75 and Buy Rating Maintained
Company Performance: JD Health reported results that exceeded expectations for Q1-Q4 2025, prompting BofA Securities to host an investor meeting with management, who expressed confidence in capturing a larger share of the pharmacy market.
Strategic Focus: The company's strategy includes enhancing cooperation with pharmaceutical firms for new drug launches, developing high-potential health supplements, and advancing a comprehensive model for medical devices that integrates hardware, software, services, and ecosystem.
Growth Forecast: BofA Securities raised its revenue growth forecast for JD Health to 18% year-over-year for 2026, primarily driven by accelerated growth in the pharmaceutical sector, while maintaining the adjusted net profit forecast at RMB6.6 billion.
Market Rating: The broker maintained a "Buy" rating for JD Health, setting a target price of $75, despite expectations of flat net profit growth for the year.
HSI Rises 435 Points as JD-SW Jumps 10% and JD LOGISTICS Soars 23%
Hong Kong Stock Market Performance: Hong Kong stocks saw significant gains, with the HSI rising 1.7% to 25,757, the HSCEI up 2.1% to 8,628, and the HSTECH increasing 3.2% to 4,947, alongside a total market turnover of $292.766 billion.
JD Series Surge: JD-SW shares surged nearly 10% to $106.6 following positive results, while JD LOGISTICS experienced a remarkable 23% increase, making it the largest gainer among blue chips.
Tech Stocks Rally: Major tech companies like TENCENT, BABA-W, and MEITUAN-W saw their stock prices rise between 3.1% and 5.2%, reflecting a broader positive trend in the tech sector.
BILIBILI-W Decline: Despite reporting a 94% increase in adjusted net profit, BILIBILI-W's stock price fell by 4.5%, contrasting with other companies that experienced gains.
HSBC Research Anticipates Continued Strong Revenue Growth for JD HEALTH (06618.HK) This Year, Raises Target Price to $80
Annual Results Announcement: JD HEALTH reported strong quarterly results, highlighting the effectiveness of its strategy focused on enhancing supply chain capabilities and user engagement, as noted by HSBC Global Research.
Competitive Advantage: The company's solid competitive position has improved user perception and strengthened partnerships with pharmaceutical firms, creating a beneficial cycle for growth.
Revenue Growth Forecast: HSBC Global Research expressed confidence in JD HEALTH's sustained revenue growth, particularly in prescription drugs, and raised its revenue forecasts for 2026 and 2027 by 1%.
Target Price Adjustment: Following a valuation update, HSBC increased JD HEALTH's target price from $77.5 to $80 while maintaining a "Buy" rating.
